EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT06138834
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Registry
-
NCT06138834
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT06138834. Randomized; quadruple masking; primary purpose treatment. Start 2023-11 (anticipated); primary completion 2024-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)
- Condition
- Acute Ischemic Stroke
- Condition
- Large Vessel Occlusion
- Condition
- Reperfusion
- Intervention (Drug)
- Low-dose Y-6 sublingual tablets
- Intervention (Drug)
- High-dose Y-6 sublingual tablets
- Intervention (Drug)
- Low-dose Cilostazol
- Intervention (Drug)
- High-dose Cilostazol
- Intervention (Drug)
- Placebo
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Neurodawn Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06138834- Content hash
8a372a70a1a2d087050c2ab16dfa39d31c01da0f70228b09b83e39029d72b0f0